Comparative Pharmacology
Head-to-head clinical analysis: SUBOXONE versus SUBUTEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SUBOXONE versus SUBUTEX.
SUBOXONE vs SUBUTEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Partial agonist at mu-opioid receptor and antagonist at kappa-opioid receptor; also antagonist at delta-opioid receptor.
Partial agonist at mu-opioid receptors; antagonist at kappa-opioid receptors. High affinity binding reduces withdrawal symptoms and blocks effects of full agonists.
Sublingual tablet: Initial dose 2-8 mg buprenorphine/0.5-2 mg naloxone on Day 1; target maintenance 12-16 mg/3-4 mg once daily; maximum 24 mg/6 mg once daily.
Sublingual tablet: initial 2-4 mg, titrated to 8-16 mg daily as a single dose; maximum 24 mg per day.
None Documented
None Documented
Buprenorphine: 37 hours (range 20-70) due to slow dissociation from mu-opioid receptors; norbuprenorphine: ~30 hours.
Terminal elimination half-life of buprenorphine ranges from 24 to 60 hours (mean ~37 hours). Clinical context: Long half-life allows for alternate-day dosing in maintenance therapy but requires careful monitoring for accumulation in renal impairment.
Buprenorphine: ~70% fecal, ~30% renal. Norbuprenorphine: ~70% renal, ~30% fecal.
Renal: approximately 30% of administered dose excreted unchanged in urine. Fecal: about 70% eliminated via feces, predominantly as conjugated metabolites. Biliary excretion contributes to fecal elimination.
Category C
Category C
Partial Opioid Agonist/Naloxone Combination
Partial Opioid Agonist